# RW Effectiveness of Lurbinectedin in Extensive Stage SCLC

> **NCT05285033** · — · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 312 (actual)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT05285033
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2023-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05285033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05285033, "RW Effectiveness of Lurbinectedin in Extensive Stage SCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05285033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*